Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?

• Main Authors: Ming-kun Chen (Author), Zhi-jian Liang (Author), Dao-Sheng Luo (Author), Kang-yi Xue (Author), De-ying Liao (Author), Zheshen Li (Author), Yuzhong Yu (Author), Zhe-Sheng Chen (Author), Shan-Chao Zhao (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: To summarize the current therapeutic status using chemotherapeutic agent docetaxel and endocrine therapeutic agents (ARAT, abiraterone, orteronel or enzalutamide) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), including sequential therapy and combined therap...